Dair approach in 7 infected total hip arthroplasties: our experience and current concepts of the literature.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
10 03 2022
10 03 2022
Historique:
received:
22
11
2021
accepted:
23
11
2021
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
26
5
2022
Statut:
epublish
Résumé
Periprosthetic joint infection (PJI) is one of the most challenging complications following total hip arthroplasty. In early infection, within four to twelve weeks from surgery, debridement, antibiotics and implant retention (DAIR) can be the initial treatment. The aim of this study is to report our case series and review current concepts reported in the literature about this topic. This was an observational cohort study that included 7 patients managed with DAIR for PJI following primary total hip replacement (THR) between 2014 and 2020. Inclusion criteria were a primary THR, direct anterior or lateral approach, DAIR procedure, and PJI. Exclusion criteria were a PJI following a revision total hip replacement or hemiarthroplasty, posterolateral approach, 1-stage revision, 2-stage revision, and Girdlestone procedure without prior DAIR. For each patient demographic characteristics, laboratory values, microorganisms involved, antibiotic therapy and outcome at one-year follow-up were registered. The mean duration between THR and DAIR was 19 days. In all cases only one DAIR procedure was performed. Most infections were caused by Staphylococcus aureus (4 cases) [one methicillin resistant (MRSA)]. The other infections were caused by Streptococcus agalactiae, Staphylococcus coagulase negative and Escherichia coli. At the final follow-up, the procedure was considered as successful in 6 out of 7 patients (85%). The one with unsuccessful outcome underwent to a two-stage revision. Our results were comparable with those of a recent systematic review of the literature. Factors that have been postulated to influence the outcome of DAIR in the management of PJIs include the timing and numbers of debridement, the exchange of components, the responsible microorganism and the duration of antibiotic treatment. In conclusion, the outcomes following DAIR are better as the indications are refined and risk factors identified. PJI prevention remains the key but the current literature still lacks well documented and effective PJI prevention protocols. (www.actabiomedica.it).
Identifiants
pubmed: 35604248
doi: 10.23750/abm.v92iS3.12603
pmc: PMC9437696
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2021572Références
N Engl J Med. 2004 Oct 14;351(16):1645-54
pubmed: 15483283
Nat Rev Dis Primers. 2018 May 31;4:18033
pubmed: 29849094
Acta Orthop. 2015 Feb;86(1):142
pubmed: 25756150
Clin Orthop Relat Res. 2002 Nov;(404):116-24
pubmed: 12439249
BMC Musculoskelet Disord. 2017 May 10;18(1):183
pubmed: 28486957
J Antimicrob Chemother. 2009 Jun;63(6):1264-71
pubmed: 19336454
Clin Orthop Relat Res. 2013 Jan;471(1):250-7
pubmed: 22552768
Antimicrob Agents Chemother. 2013 Jan;57(1):350-5
pubmed: 23114758
Orthopedics. 2009 Feb;32(2):87
pubmed: 19301804
Bone Joint J. 2016 Jan;98-B(1 Suppl A):27-30
pubmed: 26733637
JB JS Open Access. 2020 Dec 15;5(4):
pubmed: 33376927
Bone Joint J. 2017 Nov;99-B(11):1458-1466
pubmed: 29092984
Clin Infect Dis. 1997 May;24(5):914-9
pubmed: 9142792
Hip Int. 2012 Jul-Aug;22 Suppl 8:S19-24
pubmed: 22956381
Acta Biomed. 2019 Jan 15;89(4):558-563
pubmed: 30657124
Clin Orthop Relat Res. 2015 Jun;473(6):2131-8
pubmed: 25467789
Clin Infect Dis. 2009 Oct 1;49(7):1036-43
pubmed: 19691430
Orthop Clin North Am. 1984 Jul;15(3):517-35
pubmed: 6472832
J Infect. 2007 Jul;55(1):1-7
pubmed: 17343916
J Bone Joint Surg Am. 2006 Jun;88(6):1231-7
pubmed: 16757755
JAMA. 1998 May 20;279(19):1537-41
pubmed: 9605897
Int Orthop. 2020 Jan;44(1):61-68
pubmed: 31020342
Clin Infect Dis. 1992 Jun;14(6):1251-3
pubmed: 1623081
EFORT Open Rev. 2018 Jul 17;3(7):434-441
pubmed: 30233819
Clin Infect Dis. 1999 Aug;29(2):292-5
pubmed: 10476729
Bone Joint J. 2017 May;99-B(5):614-622
pubmed: 28455470
ANZ J Surg. 2016 Dec;86(12):1014-1018
pubmed: 27561596
Clin Orthop Relat Res. 2010 Aug;468(8):2029-38
pubmed: 20224958
J Bone Joint Surg Am. 1996 Apr;78(4):512-23
pubmed: 8609130
J Arthroplasty. 2011 Sep;26(6 Suppl):104-8
pubmed: 21641762
JB JS Open Access. 2020 May 09;5(2):e0062
pubmed: 33123664
J Bone Joint Surg Am. 2012 Jul 18;94(14):e104
pubmed: 22810411
Eur J Clin Microbiol Infect Dis. 2001 Jan;20(1):20-6
pubmed: 11245318
Acta Orthop. 2019 Oct;90(5):455-459
pubmed: 31132902
Antimicrob Agents Chemother. 1993 Jun;37(6):1214-8
pubmed: 8328772
Bone Joint J. 2017 Mar;99-B(3):330-336
pubmed: 28249972
Acta Orthop. 2013 Aug;84(4):380-6
pubmed: 23848215
J Antimicrob Chemother. 2012 Jul;67(7):1749-54
pubmed: 22511636
Int Orthop. 2015 Mar;39(3):397-401
pubmed: 25183296
Clin Infect Dis. 2003 Apr 1;36(7):845-9
pubmed: 12652384
Clin Orthop Relat Res. 1992 Aug;(281):216-23
pubmed: 1499215
Bull Hosp Jt Dis (2013). 2018 Mar;76(1):55-61
pubmed: 29537958
Int Orthop. 2011 Feb;35(2):253-60
pubmed: 21085957
Acta Orthop Belg. 2010 Apr;76(2):254-9
pubmed: 20503953
Acta Biomed. 2020 Dec 30;91(14-S):e2020032
pubmed: 33559627
Trends Microbiol. 2005 Jan;13(1):34-40
pubmed: 15639630
Hip Int. 2018 Nov;28(2_suppl):66-72
pubmed: 30755117
Orthop Clin North Am. 1975 Oct;6(4):991-1003
pubmed: 1178168
Orthop Traumatol Surg Res. 2011 Apr;97(2):134-8
pubmed: 21388905
Science. 1999 May 21;284(5418):1318-22
pubmed: 10334980
Clin Microbiol Rev. 2002 Apr;15(2):167-93
pubmed: 11932229
J Orthop. 2018 Mar 30;15(2):495-499
pubmed: 29643693
Acta Biomed. 2018 Dec 18;90(1-S):67-74
pubmed: 30715001